EP Patent

EP3029040A1 — Verfahren zur herstellung chiraler 8-(3-amino-piperidin-1-yl)-xanthine

Assigned to Boehringer Ingelheim International GmbH · Expires 2016-06-08 · 10y expired

What this patent protects

Die Erfindung betrifft ein verbessertes Verfahren zur Herstellung enantiomerenreiner 8-(3-Amino-piperidin-1-yl)-xanthine.

USPTO Abstract

Die Erfindung betrifft ein verbessertes Verfahren zur Herstellung enantiomerenreiner 8-(3-Amino-piperidin-1-yl)-xanthine.

Drugs covered by this patent

Patent Metadata

Patent number
EP3029040A1
Jurisdiction
EP
Classification
—
Expires
2016-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.